[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100541934":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":39,"locations":45,"responsibleParty":92,"collaborators":94,"id":104,"slug":26,"hasResults":105,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":105,"sex":111,"minAge":112,"maxAge":26,"enrollmentInfo":113,"targetDuration":26,"studyType":116,"phases":117,"briefSummary":119,"conditions":120,"keywords":124,"overallStatus":48,"whyStopped":26,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},{"fullName":5,"class":6},"Region Örebro County","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Vaccination arm","ACTIVE_COMPARATOR","Influenza vaccine (Inactivated, split virus or surface antigen Suspension for injection, prefilled syringe ATC code: J07BB02)",[13],"Biological: Influenza vaccine",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo arm","PLACEBO_COMPARATOR","Sodium Chloride (Placebo) Solution for infusion, 9mg\u002Fml ATC code: B05BB01",[19],"Biological: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"BIOLOGICAL","Influenza vaccine","Inactivated, split virus or surface antigen Suspension for injection, prefilled syringe ATC code: J07BB02",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Sodium Chloride Solution for infusion, 9mg\u002Fml ATC code: B05BB01",[15],[32,36],{"name":33,"affiliation":34,"role":35},"Sara Cajander, MD","Region Örebro län","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":34,"role":38},"Ole Frøbert, professor","STUDY_CHAIR",[40],{"name":33,"role":41,"phone":42,"phoneExt":43,"email":44},"CONTACT","+46196021042","+46196021000","sara.cajander@oru.se",[46,63,77],{"facility":47,"status":48,"city":49,"state":26,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Aarhus University Hospital, Department of Cardiology","RECRUITING","Aarhus","DK-8200","Denmark",{"type":53,"coordinates":54},"Point",[55,56],10.21076,56.15674,{"lat":56,"lon":55},[59],{"name":60,"role":41,"phone":61,"phoneExt":26,"email":62},"Bjarne Linde Nørgaard, MD, PhD","+45 78 45 00 00","bnorgaard@dadlnet.dk",{"facility":64,"status":48,"city":65,"state":26,"zip":66,"country":67,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Örebro University Hospital","Örebro","70185","Sweden",{"type":53,"coordinates":69},[70,71],15.2066,59.27412,{"lat":71,"lon":70},[74],{"name":75,"role":41,"phone":76,"phoneExt":26,"email":44},"Sara Cajander","+46702261026",{"facility":78,"status":48,"city":79,"state":26,"zip":80,"country":81,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Cambridge University Hospitals NHS Foundation Trust","Cambridge","CB2 0QQ","United Kingdom",{"type":53,"coordinates":83},[84,85],0.11667,52.2,{"lat":85,"lon":84},[88],{"name":89,"role":41,"phone":90,"phoneExt":26,"email":91},"Joseph Cheriyan, Dr","01223 336517","jc403@cam.ac.uk",{"type":93,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR",[95,97,99,101,103],{"name":96,"class":6},"The Swedish Heart and Lung Association",{"name":98,"class":6},"Örebro University, Sweden",{"name":100,"class":6},"University of Cambridge",{"name":102,"class":6},"Aarhus University Hospital",{"name":78,"class":6},"100541934",false,"NCT06336317","Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE","Effect of infLuenza vaccInation After Myocardial INfArction on Cardiac inflammaTory responsE - a Randomized, Double-blind, Placebo-controlled, Trial (ELIMINATE Trial)","ELIMINATE","Inclusion Criteria:\n\n* Patients with a diagnosis of non-ST-segment elevation myocardial infarction\n* A finalized coronary PCI\n* Male or non-fertile female subjects ≥18 years. (Females without childbearing potential, postmenopausal women and women with a history of hysterectomy or other medical conditions that preclude pregnancy)\n* Written informed consent\n* A CCTA can be scheduled within 7 days after PCI\n\nExclusion Criteria:\n\n* Has received influenza vaccination within 6 months\n* Other vaccination planned within 8 weeks (including covid-19 booster doses)\n* Severe allergy to eggs or previous allergic reaction to influenza vaccine\n* Cardiac surgery or staged PCI planned within 8 weeks\n* Coronary stent involving the proximal RCA\n* Suspicion of febrile illness or acute, ongoing infection\n* Hypersensitivity to the active substances or ingredients of Vaxigrip or against any residues, such as eggs (ovalbumin or chicken proteins), neomycin, formaldehyde and octoxinol\n* Subjects with endogenic or iatrogenic immunosuppression that may result in reduced immunization response\n* Inability to provide informed consent\n* Previous randomization in the ELIMINATE trial\n* Any non-cardiovascular condition, e.g. malignancy, with a life expectancy of less than 1 year based on the investigator´s clinical judgement.\n* Contraindication to coronary CT angiography (e.g., inability to lie flat, contraindication to glyceryl trinitrate, previous contrast allergy or contrast-induced nephropathy, severe renal impairment \\[eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2\\])\n* Atrial fibrillation\n* Uncontrolled chronic inflammatory disease\n* Unable to comply with protocol requirements","ALL","18 Years",{"count":114,"type":115},90,"ESTIMATED","INTERVENTIONAL",[118],"PHASE4","The goal of this randomized, double-blind, placebo-controlled clinical trial is to investigate the immunological effects of influenza vaccination outside of the influenza season on arterial inflammation in patients with a recent acute myocardial infarction (AMI). The primary objective is to compare the effects of influenza vaccination to those of a placebo in reducing post-myocardial infarction coronary inflammation as measured by coronary computed tomography angiography (CCTA). The main questions it aims to answer are:\n\nDoes influenza vaccination reduce arterial inflammation as measured by CCTA at week 8 after percutaneous coronary intervention (PCI) in comparison to baseline? Does influenza vaccination modulate systemic inflammation as measured by blood biomarkers and in-vitro challenge tests at week 8 after PCI in comparison to baseline? Researchers will compare the effects of influenza vaccination with those of a placebo.",[121,122,123],"Acute Myocardial Infarction","Cardiovascular Diseases","Inflammatory Response",[125,126,23,127],"Coronary computed tomography angiography","Percutaneous coronary intervention","Non ST-segment elevation myocardial infarction","2026-04-01",{"date":130,"type":131},"2026-04-07","ACTUAL",{"date":133,"type":131},"2024-04-24",{"date":135,"type":115},"2027-12",{"name":5,"class":6},3]